{"id":38128,"date":"2025-07-14T06:53:48","date_gmt":"2025-07-14T04:53:48","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/07\/14\/low-dose-il-2-reinvigorates-the-immunoguardians-of-neurodegenerative-diseases-yunbo-wei\/"},"modified":"2025-07-14T06:53:48","modified_gmt":"2025-07-14T04:53:48","slug":"low-dose-il-2-reinvigorates-the-immunoguardians-of-neurodegenerative-diseases-yunbo-wei","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/07\/14\/low-dose-il-2-reinvigorates-the-immunoguardians-of-neurodegenerative-diseases-yunbo-wei\/","title":{"rendered":"Low-dose IL-2 reinvigorates the immunoguardians of neurodegenerative diseases. Yunbo Wei"},"content":{"rendered":"<div>\n<p><b>Trends Immunol<\/b>. 2025 Jul 12:S1471-4906(25)00171-1. doi: 10.1016\/j.it.2025.07.004. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Amyotrophic lateral sclerosis (ALS) is a life-threatening neurodegenerative disease caused by motor neuron loss. In a recent Phase 2b trial, Bensimon and colleagues report that the addition of low-dose interleukin 2 (LD-IL-2) immunotherapy to standard of care (SOC) shows promise in enhancing immune tolerance and improving survival in individuals with slower disease progression.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40653411\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=100966032&amp;ff=20250714005347&amp;v=2.18.0.post9+e462414\">40653411<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.it.2025.07.004\">10.1016\/j.it.2025.07.004<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Trends Immunol. 2025 Jul 12:S1471-4906(25)00171-1. doi: 10.1016\/j.it.2025.07.004. Online ahead of print. ABSTRACT Amyotrophic lateral sclerosis (ALS) is a life-threatening neurodegenerative disease caused by motor neuron loss. In a recent Phase 2b trial, Bensimon and colleagues report that the addition of low-dose interleukin 2 (LD-IL-2) immunotherapy to standard of care (SOC) shows promise in enhancing immune &#8230; <a title=\"Low-dose IL-2 reinvigorates the immunoguardians of neurodegenerative diseases. Yunbo Wei\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/07\/14\/low-dose-il-2-reinvigorates-the-immunoguardians-of-neurodegenerative-diseases-yunbo-wei\/\" aria-label=\"Read more about Low-dose IL-2 reinvigorates the immunoguardians of neurodegenerative diseases. Yunbo Wei\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,68],"tags":[],"class_list":["post-38128","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-trends-in-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/38128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=38128"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/38128\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=38128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=38128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=38128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}